Dr. Hwyda Arafat graduated from the Faculty of Medicine of Ain Shams University in Cairo, Egypt with highest honors. Upon completing her residency in Internal Medicine and a fellowship in Clinical Pathology, she joined the faculty of Ain Shams University as an instructor of Anatomy and Histology. She received her Master’s degree in Biomedical Sciences (Histopathology/Biochemistry) and her PhD in Cell Biology and Immunology from the University of Medicine and Dentistry of New Jersey. Dr. Arafat received her postdoctoral training at the University of Pennsylvania where she served afterwards as an assistant professor in the Department of Surgery. Dr. Arafat joined the faculty of Thomas Jefferson University in 2001 at the departments of Surgery and Pathology Anatomy and Cell Biology. Dr. Arafat joined the faculty of the University of New England COM as a professor of Biomedical Sciences in 2013.
Dr. Arafat experience spans teaching, research and mentoring graduate and medical students, postdocs and residents. Her research is focused on investigating the molecular mechanisms involved in the regulation of oxidative stress and inflammation signaling in two pancreatic diseases, type 1 diabetes and pancreatic cancer. She received multiple honors and awards from federal and non-federal funding agencies in the fields of diabetes and cancer research such as the Junior Faculty Award from the American Diabetes Association and the Research Scholar Award from the American Cancer Society and from NIH. Dr. Arafat is the recepient of the Dean's Award for Excellence in Education from Thomas Jefferson University, acknowledging her excellence and innovative methods of integrating basic and clinical sciences. She has authored over 50 peer reviewed scientific papers in the fields of diabetes and pancreatic cancer. Dr. Arafat serves on the advisory boards of many funding agencies. She serves as a reviewer to different scientific journals. Dr. Arafat travels around the US and internationally teaching and lecturing about her research and the advances in treatment of type 1 diabetes and benign and malignant pancreatic diseases.
With a focus on medical education, in 2017, Dr. Arafat obtained her Master’s degree in Medical Education Leadership from the University of New England. She conducts workshops for faculty and students nationally and internationally about medical education, research and faculty development.
University of New England
University of Medicine and Dentistry of New Jersey
Ain Shams University, Cairo, Egypt
Ain Shams University, Cairo, Egypt
University of Pennsylvania
Relles D, Chipitsyna GI, Gong Q, Yeo CJ, Arafat HA. Thymoquinone Promotes
Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined
Inhibition of Histone Deacetylation and Induction of Histone Acetylation. Adv
Prev Med. 2016;2016:1407840. doi: 10.1155/2016/1407840. Epub 2016 Dec 26. PubMed
PMID: 28105374; PubMed Central PMCID: PMC5220391.
Sarosiek K, Gandhi AV, Saxena S, Kang CY, Chipitsyna GI, Yeo CJ, Arafat HA.
Hypothyroidism in Pancreatic Cancer: Role of Exogenous Thyroid Hormone in Tumor
Invasion-Preliminary Observations. J Thyroid Res. 2016;2016:2454989. doi:
10.1155/2016/2454989. Epub 2016 Mar 31. PubMed PMID: 27123358; PubMed Central
Sarosiek K, Pappan KL, Gandhi AV, Saxena S, Kang CY, McMahon H, Chipitsyna GI,
Tichansky DS, Arafat HA. Conserved Metabolic Changes in Nondiabetic and Type 2
Diabetic Bariatric Surgery Patients: Global Metabolomic Pilot Study. J Diabetes
Res. 2016;2016:3467403. doi: 10.1155/2016/3467403. Epub 2016 Jan 10. PubMed PMID:
26881244; PubMed Central PMCID: PMC4736952.
4: Sarosiek K, Jones E, Chipitsyna G, Al-Zoubi M, Kang C, Saxena S, Gandhi AV,
Sendiky J, Yeo CJ, Arafat HA. Osteopontin (OPN) isoforms, diabetes, obesity, and
cancer; what is one got to do with the other? A new role for OPN. J Gastrointest
Surg. 2015 Apr;19(4):639-50. doi: 10.1007/s11605-014-2735-6. Epub 2015 Jan 13.
PubMed PMID: 25583441.
Gulla A, Evans BJ, Navenot JM, Pundzius J, Barauskas G, Gulbinas A,
Dambrauskas Z, Arafat HA, Wang ZX. Heme oxygenase-1 gene promoter polymorphism is
associated with the development of necrotizing acute pancreatitis. Pancreas. 2014
Nov;43(8):1271-6. doi: 10.1097/MPA.0000000000000171. PubMed PMID: 25036905.
Siddiqui AA, Jones E, Andrade D, Shah A, Kowalski TE, Loren DE, Chipitsyna G,
Arafat HA. Osteopontin splice variant as a potential marker for metastatic
disease in pancreatic adenocarcinoma. J Gastroenterol Hepatol. 2014
Jun;29(6):1321-7. doi: 10.1111/jgh.12561. PubMed PMID: 24548099; PubMed Central
Al-Zoubi M, Chipitsyna G, Saxena S, Sarosiek K, Gandhi A, Kang CY, Relles D,
Andrelsendecki J, Hyslop T, Yeo CJ, Arafat HA. Overexpressing TNF-alpha in
pancreatic ductal adenocarcinoma cells and fibroblasts modifies cell survival and
reduces fatty acid synthesis via downregulation of sterol regulatory element
binding protein-1 and activation of acetyl CoA carboxylase. J Gastrointest Surg.
2014 Feb;18(2):257-68; discussion 268. doi: 10.1007/s11605-013-2370-7. Epub 2013
Oct 4. PubMed PMID: 24091913.
Kang CY, Wang J, Axell-House D, Soni P, Chu ML, Chipitsyna G, Sarosiek K,
Sendecki J, Hyslop T, Al-Zoubi M, Yeo CJ, Arafat HA. Clinical significance of
serum COL6A3 in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2014
Jan;18(1):7-15. doi: 10.1007/s11605-013-2326-y. Epub 2013 Sep 4. PubMed PMID:
Gandhi AV, Saxena S, Relles D, Sarosiek K, Kang CY, Chipitsyna G, Sendecki JA,
Yeo CJ, Arafat HA. Differential expression of cytochrome P450 omega-hydroxylase
isoforms and their association with clinicopathological features in pancreatic
ductal adenocarcinoma. Ann Surg Oncol. 2013 Dec;20 Suppl 3:S636-43. doi:
10.1245/s10434-013-3128-x. Epub 2013 Jul 12. PubMed PMID: 23846787.